Denali Therapeutics Announces FDA Has Selected Dnl126 (Etv:Sgsh) for Mps Iiia (Sanfilippo Syndrome Type a) for Start Pilot Program Intended to Accelerate Development of Rare Disease Therapies
denali therapeutics宣佈FDA已選定Dnl126(Etv:Sgsh)作爲開始試點項目的Sanfilippo A型(MPS IIIA)罕見病治療的加速開發。